Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists
| dc.contributor.author | Carroll, Camille | |
| dc.contributor.author | Fackrell, R | |
| dc.contributor.author | Grosset, D | |
| dc.contributor.author | Mohamed, B | |
| dc.contributor.author | Reddy, P | |
| dc.contributor.author | Parry, M | |
| dc.contributor.author | Chaudhuri, K | |
| dc.contributor.author | Foltynie, T | |
| dc.date.accessioned | 2018-07-06T11:01:26Z | |
| dc.date.issued | 2018-10 | |
| dc.identifier.issn | 1758-2024 | |
| dc.identifier.issn | 1758-2032 | |
| dc.identifier.uri | http://hdl.handle.net/10026.1/11813 | |
| dc.description.abstract |
In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales. | |
| dc.format.extent | 349-360 | |
| dc.format.medium | Print-Electronic | |
| dc.language | en | |
| dc.language.iso | en | |
| dc.publisher | Future Medicine | |
| dc.subject | Parkinson's disease | |
| dc.subject | opicapone | |
| dc.subject | safinamide | |
| dc.subject | Antiparkinson Agents | |
| dc.subject | Humans | |
| dc.subject | Parkinson Disease | |
| dc.title | Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists | |
| dc.type | journal-article | |
| dc.type | Consensus Development Conference | |
| dc.type | Journal Article | |
| dc.type | Research Support, Non-U.S. Gov't | |
| plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/29975112 | |
| plymouth.issue | 5 | |
| plymouth.volume | 8 | |
| plymouth.publication-status | Published | |
| plymouth.journal | Neurodegenerative Disease Management | |
| dc.identifier.doi | 10.2217/nmt-2018-0020 | |
| plymouth.organisational-group | /Plymouth | |
| plymouth.organisational-group | /Plymouth/00 Groups by role | |
| plymouth.organisational-group | /Plymouth/00 Groups by role/Academics | |
| plymouth.organisational-group | /Plymouth/Faculty of Medicine and Dentistry | |
| plymouth.organisational-group | /Plymouth/Faculty of Medicine and Dentistry/Centre for Clinical Trials & Health Research | |
| plymouth.organisational-group | /Plymouth/Faculty of Medicine and Dentistry/Centre for Clinical Trials & Health Research/RC reporting group CTPS | |
| plymouth.organisational-group | /Plymouth/Faculty of Medicine and Dentistry/Collaboration for the Advancement of Medical Education Research Assessment | |
| plymouth.organisational-group | /Plymouth/Faculty of Medicine and Dentistry/Neuroscience | |
| plymouth.organisational-group | /Plymouth/Research Groups | |
| plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
| plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
| dc.publisher.place | England | |
| dcterms.dateAccepted | 2018-06-19 | |
| dc.rights.embargodate | 2018-8-3 | |
| dc.identifier.eissn | 1758-2032 | |
| dc.rights.embargoperiod | Not known | |
| rioxxterms.versionofrecord | 10.2217/nmt-2018-0020 | |
| rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
| rioxxterms.type | Journal Article/Review |
